Mode
Text Size
Log in / Sign up
Phase 4 Completed N=20 Diagnostic

Stress Testing and Cardiac Magnetic Resonance

Coronary Disease
Source: ClinicalTrials.gov NCT00871260 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Major Adverse Cardiovascular Events — 0 Participants
◆ Published Evidence
Established
45citations · ~3 / year
Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson.
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2012 · Open access · Likely link

Summary

The purpose of this study is to better define the role of a comprehensive stress MRI (which includes myocardial perfusion imaging, optimized coronary imaging, and myocardial scar imaging) in medical practice and in patient health management. Information gathered from the healthy volunteers that participate in this study will be compared to information from the coronary artery disease patients in this study in order to help further our understanding.

Linked Publications

  • Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson.
    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2012 · 45 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Major Adverse Cardiovascular Events
SECONDARY
Relationship Between SPECT and CMR Results of Myocardial Perfusion Imaging
SECONDARY
Optimization of Coronary Imaging Using CMR

Eligibility Criteria

Inclusion Criteria

  • Suspected coronary artery disease
  • Symptoms of possible coronary artery disease

Exclusion Criteria

  • Acute ST-elevation myocardial infarction
  • Second or third degree AV block
  • Severe Renal Disease (Glomerular Filtration Rate (GFR) <30cc/min or hemodialysis)
  • Contra-indications to MRI (i.e. Implantable Cardioverter Defibrillator (ICD), pacemaker, aneurysm clip, etc)
  • Hemodynamic instability
  • Inability to provide informed consent
  • Severe claustrophobia
  • Pregnancy
  • Age <18 years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00871260) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search